# The Effects of TMZ on Diabetic Nephropathy

Study · id `cardio:ct-nct05147194` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05147194](<https://clinicaltrials.gov/study/NCT05147194>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05147194

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.

## Technical summary

Registry record NCT05147194. Randomized; no masking; primary purpose treatment. Start 2022-01-01 (anticipated); primary completion 2023-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT05147194, source copy `cardio:ctgov-nct05147194-2021-12-07`, retrieved 2026-10-26)
- Planned start: 2022-01-01 (anticipated) (ClinicalTrials.gov record NCT05147194, source copy `cardio:ctgov-nct05147194-2021-12-07`, retrieved 2026-10-26)
- Primary completion: 2023-12-31 (anticipated) (ClinicalTrials.gov record NCT05147194, source copy `cardio:ctgov-nct05147194-2021-12-07`, retrieved 2026-10-26)
- Completion: 2023-12-31 (anticipated) (ClinicalTrials.gov record NCT05147194, source copy `cardio:ctgov-nct05147194-2021-12-07`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05147194-2021-12-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Effects of TMZ on Diabetic Nephropathy
- Condition: Diabetic Nephropathies
- Intervention (Drug): Trimetazidine
- Lead sponsor: Tongji Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Tongji Hospital (`cardio:org-tongji-hospital`)

## Provenance

Content hash: 122a61050e84b5855337466c830184b7ae6a7329b60683eab8f5d482a390a451
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
